342 related articles for article (PubMed ID: 20708412)
41. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
Harbeck N; Kates RE; Gauger K; Willems A; Kiechle M; Magdolen V; Schmitt M
Thromb Haemost; 2004 Mar; 91(3):450-6. PubMed ID: 14983219
[TBL] [Abstract][Full Text] [Related]
42. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
Duffy MJ; Duggan C
Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
[TBL] [Abstract][Full Text] [Related]
43. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
[TBL] [Abstract][Full Text] [Related]
44. Progress of tissue injury in appendicitis involves the serine proteases uPA and PAI-1.
Solberg A; Holmdahl L; Falk P; Willén R; Palmgren I; Ivarsson ML
Scand J Gastroenterol; 2009; 44(5):579-84. PubMed ID: 19153874
[TBL] [Abstract][Full Text] [Related]
45. Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors.
Kumamoto H; Ooya K
J Oral Pathol Med; 2007 Sep; 36(8):488-94. PubMed ID: 17686008
[TBL] [Abstract][Full Text] [Related]
46. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
Offersen BV; Pfeiffer P; Andreasen P; Overgaard J
Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889
[TBL] [Abstract][Full Text] [Related]
47. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
48. Buerger's disease and anticardiolipin antibodies.
Pereira de Godoy JM; Braile DM
J Cardiovasc Med (Hagerstown); 2009 Oct; 10(10):792-4. PubMed ID: 19455050
[TBL] [Abstract][Full Text] [Related]
49. Buerger's syndrome.
Herman BE
Angiology; 1975 Nov; 26(10):713-6. PubMed ID: 1053580
[TBL] [Abstract][Full Text] [Related]
50. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
Taponeco F; Curcio C; Giuntini A; Nardini V; Fornaciari G; Artini PG; D'Ambrogio G; Genazzani AR
J Exp Clin Cancer Res; 2001 Jun; 20(2):239-46. PubMed ID: 11484981
[TBL] [Abstract][Full Text] [Related]
51. Plasminogen activators and plasminogen activator inhibitor 1 before and after venous occlusion of the upper limb in thromboangiitis obliterans (Buerger's disease).
Choudhury NA; Pietraszek MH; Hachiya T; Baba S; Sakaguchi S; Takada Y; Takada A
Thromb Res; 1992 May; 66(4):321-9. PubMed ID: 1412199
[TBL] [Abstract][Full Text] [Related]
52. Comparison of quality of life in patients with peripheral arterial disease caused by atherosclerosis obliterans or Buerger's disease.
Karakoyun R; Köksoy C; Şener Z; Gündüz U; Karakaş B; Karakoyun M
Cardiovasc J Afr; 2014; 25(3):124-9. PubMed ID: 25000442
[TBL] [Abstract][Full Text] [Related]
53. Thromboangiitis obliterans: classic and new morphological features.
Kurata A; Franke FE; Machinami R; Schulz A
Virchows Arch; 2000 Jan; 436(1):59-67. PubMed ID: 10664163
[TBL] [Abstract][Full Text] [Related]
54. Pathology and pathogenesis of Buerger's disease.
Tanaka K
Int J Cardiol; 1998 Oct; 66 Suppl 1():S237-42. PubMed ID: 9951825
[TBL] [Abstract][Full Text] [Related]
55. Buerger's disease in the 21st century: diagnosis, clinical features, and therapy.
Mills JL
Semin Vasc Surg; 2003 Sep; 16(3):179-89. PubMed ID: 12975757
[TBL] [Abstract][Full Text] [Related]
56. Increased Serum HMGB-1, ICAM-1 and Metalloproteinase-9 Levels in Buerger's Patients.
De Caridi G; Bitto A; Massara M; Pallio G; Pizzino G; Serra R; Altavilla D; Squadrito F; Spinelli F
Curr Vasc Pharmacol; 2016; 14(4):382-7. PubMed ID: 26935815
[TBL] [Abstract][Full Text] [Related]
57. Buerger's disease or Buerger's syndrome? An analysis of 12 cases.
Scharf GM; van Wyk FA; Cloete GN; Rautenbach BK
S Afr Med J; 1986 Dec; 70(13):803-5. PubMed ID: 3798265
[TBL] [Abstract][Full Text] [Related]
58. Thromboangiitis obliterans (Buerger's disease) in an elderly man after cessation of cigarette smoking--a case report.
Lie JT
Angiology; 1987 Nov; 38(11):864-7. PubMed ID: 3688555
[TBL] [Abstract][Full Text] [Related]
59. Buerger's disease in a young woman.
Leavitt RY; Bressler P; Fauci AS
Am J Med; 1986 May; 80(5):1003-5. PubMed ID: 3706362
[TBL] [Abstract][Full Text] [Related]
60. Immunohistochemical analysis of several proteolytic enzymes as parameters of cartilage degradation.
Walter H; Kawashima A; Nebelung W; Neumann W; Roessner A
Pathol Res Pract; 1998; 194(2):73-81. PubMed ID: 9584319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
